Name a biological therapy used in severe asthma management.

Name a biological therapy used in severe asthma management.

• A. Montelukast (Singulair)
• B. Omalizumab (Xolair)
• C. Albuterol (Ventolin)
• D. Fluticasone (Flovent)

Answer: (B)

Omalizumab (Xolair) is a biological therapy specifically designed for the management of severe asthma, particularly in patients with allergic asthma. As a monoclonal antibody, it works by binding to immunoglobulin E (IgE), which is an important mediator in allergic responses that can exacerbate asthma symptoms. By inhibiting IgE, Omalizumab reduces the frequency and severity of asthma attacks, helping to improve overall control of the disease in individuals who have not responded adequately to standard treatments. In contrast, Montelukast (Singulair), while used in asthma management, is a leukotriene receptor antagonist focused on controlling inflammation rather than being a biological therapy. Albuterol (Ventolin) is a short-acting beta-agonist primarily used for quick relief of asthma symptoms but does not address the underlying inflammation associated with severe asthma. Fluticasone (Flovent) is an inhaled corticosteroid that helps reduce inflammation but is not classified as a biological therapy. Thus, Omalizumab stands out as the correct answer due to its specific mechanism of action and role in treating severe asthma.

Omalizumab (Xolair) is a biological therapy specifically designed for the management of severe asthma, particularly in patients with allergic asthma. As a monoclonal antibody, it works by binding to immunoglobulin E (IgE), which is an important mediator in allergic responses that can exacerbate asthma symptoms. By inhibiting IgE, Omalizumab reduces the frequency and severity of asthma attacks, helping to improve overall control of the disease in individuals who have not responded adequately to standard treatments.

In contrast, Montelukast (Singulair), while used in asthma management, is a leukotriene receptor antagonist focused on controlling inflammation rather than being a biological therapy. Albuterol (Ventolin) is a short-acting beta-agonist primarily used for quick relief of asthma symptoms but does not address the underlying inflammation associated with severe asthma. Fluticasone (Flovent) is an inhaled corticosteroid that helps reduce inflammation but is not classified as a biological therapy. Thus, Omalizumab stands out as the correct answer due to its specific mechanism of action and role in treating severe asthma.